Difference between revisions of "Xu"

(Imported from Wikispaces)
 
Line 1: Line 1:
−
'''<span style="font-family: &#39;Times New Roman&#39;,&#39;serif&#39;; font-size: 16px;">Hyperbaric oxygenation may have reduced the incidence of sepsis associated with thermal burns. </span>'''
 
  
−
**<span style="font-family: &#39;Times New Roman&#39;,&#39;serif&#39;; font-size: 16px;">Clinical Bottom Line:</span>'''
+
<span style="font-size:x-large;">'''<span style="font-family: " times="" new="" roman",="" serif;"="">Hyperbaric oxygenation may have reduced the incidence of sepsis associated with thermal burns.</span>'''</span>
−
<span style="font-family: &#39;Times New Roman&#39;,&#39;serif&#39;; font-size: 16px;">1. Apparent reduction in the incidence of sepsis following thermal burns with the addition of hyperbaric oxygenation to a therapeutic regime.</span>
 
  
−
**<span style="font-family: &#39;Times New Roman&#39;,&#39;serif&#39;; font-size: 16px;">Citation:</span>'''
+
'''<span style="font-family: 'Times New Roman','serif'; font-size: 16px;">Clinical Bottom Line:</span>'''
−
<span style="font-family: &#39;Times New Roman&#39;,&#39;serif&#39;; font-size: 16px;">Xu N, Li Z, Luo X. [Effects of hyperbaric oxygen therapy on the changes in serum sIL-2R and Fn in severe burn patients]. Zhonghua Zheng Xing Shao Shang Wai Ke Za Zhi 1999; 15(3):220-223. </span>
 
−
<span style="font-family: &#39;Times New Roman&#39;,&#39;serif&#39;; font-size: 16px;">Lead author's name and fax: </span>
 
  
−
**<span style="font-family: &#39;Times New Roman&#39;,&#39;serif&#39;; font-size: 16px;">Three-part Clinical Question:</span>'''<span style="font-family: &#39;Times New Roman&#39;,&#39;serif&#39;; font-size: 16px;"> For patients with thermal burns, does the addition of hyperbaric oxygenation to a standard therapeutic regimen reduce the incidence of burn infection?</span>
+
<span style="font-family: 'Times New Roman','serif'; font-size: 16px;">1. Apparent reduction in the incidence of sepsis following thermal burns with the addition of hyperbaric oxygenation to a therapeutic regime.</span>
−
<span style="font-family: &#39;Times New Roman&#39;,&#39;serif&#39;; font-size: 16px;">Search Terms: Hyperbaric oxygenation, Burns thermal </span>
 
  
−
**<span style="font-family: &#39;Times New Roman&#39;,&#39;serif&#39;; font-size: 16px;">The Study:</span>'''
+
'''​​​​​​​<span style="font-family: 'Times New Roman','serif'; font-size: 16px;">Citation:&nbsp;</span>'''<span style="font-family: 'Times New Roman','serif'; font-size: 16px;">1.&nbsp;Xu N, Li Z, Luo X. [Effects of hyperbaric oxygen therapy on the changes in serum sIL-2R and Fn in severe burn patients]. Zhonghua Zheng Xing Shao Shang Wai Ke Za Zhi 1999; 15(3):220-223. </span> <span style="font-family: 'Times New Roman','serif'; font-size: 16px;">Lead author's name and fax:</span>
−
<span style="font-family: &#39;Times New Roman&#39;,&#39;serif&#39;; font-size: 16px;">Non-blinded randomised controlled trial with intention-to-treat unknown.</span>
 
−
<span style="font-family: &#39;Times New Roman&#39;,&#39;serif&#39;; font-size: 16px;">The Study Patients: Patients with >30% body surface area burns (or 3rd degree >10%BSA).</span>
 
−
<span style="font-family: &#39;Times New Roman&#39;,&#39;serif&#39;; font-size: 16px;">Control group (N = 17): Not stated </span>
 
−
<span style="font-family: &#39;Times New Roman&#39;,&#39;serif&#39;; font-size: 16px;">Experimental group (N = 25: HBO regimen not stated </span>
 
  
−
**<span style="font-family: &#39;Times New Roman&#39;,&#39;serif&#39;; font-size: 16px;">The Evidence:</span>'''
+
'''​​​​​​​<span style="font-family: 'Times New Roman','serif'; font-size: 16px;">Three-part Clinical Question:</span>''''''<span style="font-family: 'Times New Roman','serif'; font-size: 16px;"></span>'''<span style="font-family: 'Times New Roman','serif'; font-size: 16px;">For patients with thermal burns, does the addition of hyperbaric oxygenation to a standard therapeutic regimen reduce the incidence of burn infection?</span>
  
−
{|
+
<span style="font-family: 'Times New Roman','serif'; font-size: 16px;">'''Search Terms:''' Hyperbaric oxygenation, Burns thermal</span>
−
| '''<span style'''"font-family: &#39;Times New Roman&#39;,&#39;serif&#39;;">Non-Event Outcomes</span>''' || <span style'''"display: block; text-align: center;"><span style'''"display: block; text-align: center;">'''<span style'''"font-family: &#39;Times New Roman&#39;,&#39;serif&#39;;">Time to outcome</span>'''</span></span> || <span style'''"display: block; text-align: center;"><span style'''"display: block; text-align: center;">'''<span style'''"font-family: &#39;Times New Roman&#39;,&#39;serif&#39;;">Control group</span>'''</span></span> || <span style'''"display: block; text-align: center;"><span style'''"display: block; text-align: center;">'''<span style'''"font-family: &#39;Times New Roman&#39;,&#39;serif&#39;;">HBO group</span>'''</span></span> || <span style'''"display: block; text-align: center;"><span style'''"display: block; text-align: center;">'''<span style="font-family: &#39;Times New Roman&#39;,&#39;serif&#39;;">P-value</span>'''</span></span>
+
 
 +
'''​​​​​​​<span style="font-family: 'Times New Roman','serif'; font-size: 16px;">The Study:&nbsp;</span>'''<span style="font-family: 'Times New Roman','serif'; font-size: 16px;">Non-blinded randomised controlled trial with intention-to-treat unknown.</span> <span style="font-family: 'Times New Roman','serif'; font-size: 16px;">The Study Patients: Patients with >30% body surface area burns (or 3rd degree >10%BSA).</span> <span style="font-family: 'Times New Roman','serif'; font-size: 16px;">Control group (N = 17): Not stated </span> <span style="font-family: 'Times New Roman','serif'; font-size: 16px;">Experimental group (N = 25: HBO regimen not stated</span>
 +
 
 +
'''​​​​​​​<span style="font-family: 'Times New Roman','serif'; font-size: 16px;">The Evidence:</span>'''
 +
 
 +
{| class="Table" style="border:solid windowtext 1.0pt"
 
|-
 
|-
−
| '''<span style'''"font-family: &#39;Times New Roman&#39;,&#39;serif&#39;;">Incidence of sepsis</span>''' || <span style'''"display: block; text-align: center;"><span style'''"display: block; font-family: &quot;Times New Roman&quot;,serif; font-size: 16px; text-align: center;">35 days</span></span> || <span style'''"display: block; text-align: center;"><span style'''"display: block; font-family: &quot;Times New Roman&quot;,serif; font-size: 16px; text-align: center;">?</span></span> || <span style'''"display: block; text-align: center;"><span style'''"display: block; font-family: &quot;Times New Roman&quot;,serif; font-size: 16px; text-align: center;">Reduced</span></span> || <span style'''"display: block; text-align: center;"><span style="display: block; font-family: &quot;Times New Roman&quot;,serif; font-size: 16px; text-align: center;">P <0.05</span></span>  
+
| style="width:146.35pt; border:solid windowtext 1.0pt" width="198" |
 +
<span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">Non-Event Outcomes</span></span>'''</span>
 +
 
 +
| style="width:76.45pt; border:solid windowtext 1.0pt" width="104" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">Time to outcome</span></span>'''</span></p>
 +
| style="width:76.5pt; border:solid windowtext 1.0pt" width="104" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">Control group</span></span>'''</span></p>
 +
| style="width:76.45pt; border:solid windowtext 1.0pt" width="104" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">HBO group</span></span>'''</span></p>
 +
| style="width:66.05pt; border:solid windowtext 1.0pt" width="91" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">P-value</span></span>'''</span></p>  
 
|-
 
|-
−
| '''<span style'''"font-family: &#39;Times New Roman&#39;,&#39;serif&#39;;">Serum soluble interleukin 2 receptor</span>''' || <span style'''"display: block; text-align: center;"><span style'''"display: block; font-family: &quot;Times New Roman&quot;,serif; font-size: 16px; text-align: center;">35 days</span></span> || <span style'''"display: block; text-align: center;"><span style'''"display: block; font-family: &quot;Times New Roman&quot;,serif; font-size: 16px; text-align: center;">?</span></span> || <span style'''"display: block; text-align: center;"><span style'''"display: block; font-family: &quot;Times New Roman&quot;,serif; font-size: 16px; text-align: center;">Not increased</span></span> || <span style'''"display: block; text-align: center;"><span style="display: block; font-family: &quot;Times New Roman&quot;,serif; font-size: 16px; text-align: center;">P <0.05</span></span>  
+
| style="width:146.35pt; border:solid windowtext 1.0pt" width="198" |
 +
<span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">Incidence of sepsis</span></span>'''</span>
 +
 
 +
| style="width:76.45pt; border:solid windowtext 1.0pt" width="104" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">35 days</span></span></span></p>
 +
| style="width:76.5pt; border:solid windowtext 1.0pt" width="104" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">?</span></span></span></p>
 +
| style="width:76.45pt; border:solid windowtext 1.0pt" width="104" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">Reduced</span></span></span></p>
 +
| style="width:66.05pt; border:solid windowtext 1.0pt" width="91" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">P <0.05</span></span></span></p>  
 
|-
 
|-
−
| '''<span style'''"font-family: &#39;Times New Roman&#39;,&#39;serif&#39;;">Plasma fibronectin</span>''' || <span style'''"display: block; text-align: center;"><span style'''"display: block; font-family: &quot;Times New Roman&quot;,serif; font-size: 16px; text-align: center;">35 days</span></span> || <span style'''"display: block; text-align: center;"><span style'''"display: block; font-family: &quot;Times New Roman&quot;,serif; font-size: 16px; text-align: center;">?</span></span> || <span style'''"display: block; text-align: center;"><span style'''"display: block; font-family: &quot;Times New Roman&quot;,serif; font-size: 16px; text-align: center;">Not decreased</span></span> || <span style'''"display: block; text-align: center;"><span style="display: block; font-family: &quot;Times New Roman&quot;,serif; font-size: 16px; text-align: center;">P < 0.01</span></span>  
+
| style="width:146.35pt; border:solid windowtext 1.0pt" width="198" |
 +
<span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">Serum soluble interleukin 2 receptor</span></span>'''</span>
 +
 
 +
| style="width:76.45pt; border:solid windowtext 1.0pt" width="104" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">35 days</span></span></span></p>
 +
| style="width:76.5pt; border:solid windowtext 1.0pt" width="104" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">?</span></span></span></p>
 +
| style="width:76.45pt; border:solid windowtext 1.0pt" width="104" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">Not increased</span></span></span></p>
 +
| style="width:66.05pt; border:solid windowtext 1.0pt" width="91" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">P <0.05</span></span></span></p>  
 
|-
 
|-
 +
| style="width:146.35pt; border:solid windowtext 1.0pt" width="198" |
 +
<span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">Plasma fibronectin</span></span>'''</span>
 +
 +
| style="width:76.45pt; border:solid windowtext 1.0pt" width="104" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">35 days</span></span></span></p>
 +
| style="width:76.5pt; border:solid windowtext 1.0pt" width="104" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">?</span></span></span></p>
 +
| style="width:76.45pt; border:solid windowtext 1.0pt" width="104" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">Not decreased</span></span></span></p>
 +
| style="width:66.05pt; border:solid windowtext 1.0pt" width="91" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family:" times="" new="" roman",serif"="">P < 0.01</span></span></span></p>
 
|}
 
|}
 +
&nbsp;
 +
'''​​​​​​​<span style="font-family: 'Times New Roman','serif'; font-size: 16px;">Comments:</span>'''
 +
 +
<span style="font-family: 'Times New Roman','serif'; font-size: 16px;">1. Abstract only, little data given.</span>
 +
 +
<span style="font-family: 'Times New Roman','serif'; font-size: 16px;">2. No details of randomization method, control therapy or hyperbaric schedule.</span>
 +
 +
<span style="font-family: 'Times New Roman','serif'; font-size: 16px;">3. Clinical impact unknown.</span>
 +
 +
<span style="font-family: 'Times New Roman','serif'; font-size: 16px;">4. Soluble interleukin 2 receptors in the serum are increased and plasma fibronectin is decreased in patients with burns and they are both apparently markers for burn infection. These markers were not significantly different in HBO treated subjects when compared to healthy, non-burned controls.</span>
  
−
**<span style="font-family: &#39;Times New Roman&#39;,&#39;serif&#39;; font-size: 16px;">Comments:</span>'''
+
<span style="font-family: 'Times New Roman','serif'; font-size: 16px;">5. Article in Chinese, not yet available in translation.</span>
−
<span style="font-family: &#39;Times New Roman&#39;,&#39;serif&#39;; font-size: 16px;">1. Abstract only, little data given.</span>
 
−
<span style="font-family: &#39;Times New Roman&#39;,&#39;serif&#39;; font-size: 16px;">2. No details of randomization method, control therapy or hyperbaric schedule.</span>
 
−
<span style="font-family: &#39;Times New Roman&#39;,&#39;serif&#39;; font-size: 16px;">3. Clinical impact unknown.</span>
 
−
<span style="font-family: &#39;Times New Roman&#39;,&#39;serif&#39;; font-size: 16px;">4. Soluble interleukin 2 receptors in the serum are increased and plasma fibronectin is decreased in patients with burns and they are both apparently markers for burn infection. These markers were not significantly different in HBO treated subjects when compared to healthy, non-burned controls.</span>
 
−
<span style="font-family: &#39;Times New Roman&#39;,&#39;serif&#39;; font-size: 16px;">5. Article in Chinese, not yet available in translation. </span>
 
  
−
**<span style="font-family: &#39;Times New Roman&#39;,&#39;serif&#39;; font-size: 16px;">Appraised by:</span>'''<span style="font-family: &#39;Times New Roman&#39;,&#39;serif&#39;; font-size: 16px;"> Mike Bennett and Juliette Leverment, Hyperbaric Medicine, Prince of Wales Hospital, Sydney ; Monday, 9 December 2002</span>
+
'''​​​​​​​<span style="font-family: 'Times New Roman','serif'; font-size: 16px;">Appraised by:</span>''''''<span style="font-family: 'Times New Roman','serif'; font-size: 16px;"></span>'''<span style="font-family: 'Times New Roman','serif'; font-size: 16px;">Mike Bennett and Juliette Leverment, Hyperbaric Medicine, Prince of Wales Hospital, Sydney&nbsp;; Monday, 9 December 2002</span>
−
<span style="font-family: &#39;Times New Roman&#39;,&#39;serif&#39;; font-size: 16px;">Email: m.bennett@unsw.edu.au </span>
 
−
<span style="font-family: &#39;Times New Roman&#39;,&#39;serif&#39;; font-size: 16px;">Kill or Update By: December 2024</span>
 
  
−
<span style="display: block; text-align: center;">
+
<span style="font-family: 'Times New Roman','serif'; font-size: 16px;">'''Email:''' m.bennett@unsw.edu.au </span> <span style="font-family: 'Times New Roman','serif'; font-size: 16px;">Kill or Update By: December 2024</span>
  
−
</span>
+
&nbsp;
  
−
[[File:sumhorsa.gif|center]]
+
&nbsp;
  
 +
[[File:Sumhorsa.gif|center|Sumhorsa.gif]]
  
 +
&nbsp;
  
−
<span style="color: #7c00ff; display: block; font-size: 26px; text-align: center;">'''[[Burns | BACK]]'''</span>
+
<span style="color: #7c00ff; display: block; font-size: 26px; text-align: center;">'''[[Burns|BACK]]'''</span>

Revision as of 22:09, 24 May 2020

Hyperbaric oxygenation may have reduced the incidence of sepsis associated with thermal burns.

Clinical Bottom Line:

1. Apparent reduction in the incidence of sepsis following thermal burns with the addition of hyperbaric oxygenation to a therapeutic regime.

​​​​​​​Citation: 1. Xu N, Li Z, Luo X. [Effects of hyperbaric oxygen therapy on the changes in serum sIL-2R and Fn in severe burn patients]. Zhonghua Zheng Xing Shao Shang Wai Ke Za Zhi 1999; 15(3):220-223. Lead author's name and fax:

'​​​​​​​Three-part Clinical Question:'For patients with thermal burns, does the addition of hyperbaric oxygenation to a standard therapeutic regimen reduce the incidence of burn infection?

Search Terms: Hyperbaric oxygenation, Burns thermal

​​​​​​​The Study: Non-blinded randomised controlled trial with intention-to-treat unknown. The Study Patients: Patients with >30% body surface area burns (or 3rd degree >10%BSA). Control group (N = 17): Not stated Experimental group (N = 25: HBO regimen not stated

​​​​​​​The Evidence:

Non-Event Outcomes

Time to outcome

Control group

HBO group

P-value

Incidence of sepsis

35 days

?

Reduced

P <0.05

Serum soluble interleukin 2 receptor

35 days

?

Not increased

P <0.05

Plasma fibronectin

35 days

?

Not decreased

P < 0.01

  ​​​​​​​Comments:

1. Abstract only, little data given.

2. No details of randomization method, control therapy or hyperbaric schedule.

3. Clinical impact unknown.

4. Soluble interleukin 2 receptors in the serum are increased and plasma fibronectin is decreased in patients with burns and they are both apparently markers for burn infection. These markers were not significantly different in HBO treated subjects when compared to healthy, non-burned controls.

5. Article in Chinese, not yet available in translation.

'​​​​​​​Appraised by:'Mike Bennett and Juliette Leverment, Hyperbaric Medicine, Prince of Wales Hospital, Sydney ; Monday, 9 December 2002

Email: m.bennett@unsw.edu.au Kill or Update By: December 2024

 

 

Sumhorsa.gif

 

BACK

Retrieved from "http://hboevidence.wikis.unsw.edu.au/index.php?title=Xu&oldid=692"